Pursuant to section 23 of the Medicines Act 1981, the Minister of Health hereby provisionally consents to the sale, supply or use in New Zealand of the new medicine set out in the Schedule hereto:
Schedule
Product: Exelon
Active Ingredient(s): Rivastigmine hydrogen tartrate 3.2mg/mL equivalent to 2mg/mL rivastigmine base
Dosage Form: Oral solution
New Zealand Sponsor: Novartis New Zealand Limited
Manufacturer(s): Novartis Pharma SA, Orleans Cedex 2, France
Note: This consent is valid for 2 years from the date of publication of this notice.
Dated this 19th day of July 2000.
G. R. BOYD, Chief Advisor, Safety and Regulation (pursuant to delegation given by the Minister of Health on the 20th day of February 1997).